CytomX Therapeutics (CTMX) Q4 2025 earnings summary

Executive summary

• Positive Phase I data for Varseta-M (varsetatug masetecan), an EpCAM-targeting ADC, in late-line metastatic colorectal cancer (CRC) demonstrated robust antitumor activity and a manageable safety profile, supporting advancement toward registrational studies, with FDA discussions planned for 2026.

• Varseta-M is designed to overcome toxicity challenges of prior EpCAM-targeted therapies, with safety optimization strategies such as adjusted ideal body weight dosing and dual prophylaxis reducing gastrointestinal toxicity.

• The program aims for rapid advancement into registrational studies, expansion into earlier CRC lines, and other EpCAM-positive tumors, with combination studies (e.g., with bevacizumab) underway.

• Multiple clinical milestones and FDA interactions are anticipated in 2026, with the goal of first approval as monotherapy in late-line CRC and future expansion into additional indications.

• Research collaborations continue with major partners, though the Astellas collaboration was terminated in Q2 2026.

Financial highlights

• Cash, cash equivalents, and investments totaled $137.1 million as of December 31, 2025, up from $100.6 million at year-end 2024.

• Total revenue for 2025 was $76.2 million, down from $138.1 million in 2024, primarily due to completion of obligations with Bristol Myers Squibb and lower collaboration revenue.

• Operating expenses decreased to $98.6 million in 2025 from $113.1 million in 2024, reflecting cost control and restructuring.

• Net loss for 2025 was $17.4 million, compared to net income of $31.9 million in 2024.

• The call focused on clinical data; financial results were summarized in a press release and SEC filings referenced during the call.

Outlook and guidance

• Registrational studies for Varseta-M in late-line CRC are planned to start in H1 2027, with additional data and study design details expected in H2 2026.

• Multiple clinical milestones are anticipated over the next 12–18 months, including additional Phase I data, initiation of combination studies, and potential start of registrational trials.

• Cash runway is expected to last through the second quarter of 2027.

• Initial proof-of-concept data for CX-801 in combination with KEYTRUDA® anticipated by end of 2026.